Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) saw an uptick in trading volume on Monday. Approximately 124,635 shares changed hands during trading, an increase of 14% from the average daily volume of 109,507 shares. The stock last traded at $4.76 and had previously closed at $4.31.
Analyst Upgrades and Downgrades
Several brokerages have commented on GYRE. Weiss Ratings restated a “sell (d-)” rating on shares of Gyre Therapeutics in a research note on Wednesday, November 4th. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. Finally, Wall Street Zen raised shares of Gyre Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce”.
Get Our Latest Stock Analysis on GYRE
Gyre Therapeutics Stock Performance
The stock has a market capitalization of $547.77 million, a PE ratio of -23.60 and a beta of 2.14. The business’s 50-day moving average price is $6.30 and its 200 day moving average price is $6.81.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.19. Gyre Therapeutics had a negative return on equity of 7.39% and a negative net margin of 14.80%. The company had revenue of $32.93 million for the quarter, compared to the consensus estimate of $28.40 million. As a group, equities research analysts predict that Gyre Therapeutics, Inc. will post -0.61 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Gyre Therapeutics during the second quarter worth approximately $6,550,000. Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at $414,000. Deutsche Bank AG bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at $118,000. Dimensional Fund Advisors LP grew its holdings in shares of Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock valued at $176,000 after purchasing an additional 14,365 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in Gyre Therapeutics in the 2nd quarter worth $83,000. 23.99% of the stock is currently owned by institutional investors.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.
Read More
- Five stocks we like better than Gyre Therapeutics
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
